doi: 10.1210/er.2017-00191 18 HanlanMEGriffithJPatelNJaserSS
However, an effort to change this and allow Medicare to cover obesity medications is within the Federal Treat and Reduce Obesity Act legislation (see sidebar Resources).1 Reference 1
GLP-1 medications may reduce baseline hunger, but they do not directly address impulsive eating, emotional triggers that induce binging, or the reward response often felt with certain foods
Apart from other genes, glutathione S-transferase Mu class gene (GSTM1) from the human genome has been edited using CRISPR-Cas9 system (Sanjana et al., 2014)
Final Thoughts BPC-157 peptide therapy continues gaining attention in wellness and recovery-focused care, but patients should understand that peptide therapy is not risk-free
The Oyikey patches likely contain far lower amounts of active GLP-1 medication than implied, or possibly none at all